49 / 78
DCMS online
. org
Northeast Florida Medicine
Vol. 66, No. 4 2015
49
Inflammatory Bowel Disease
References
1.
Ardizzone S, Puttini PS, Cassinotti A, Porro GB.
Extraintestinal manifestations of inflammatory
bowel disease.
Digestive Liver Dis.
2008 Jul;40 Suppl
2:S253-259
2.
Das KM. Relationship of extraintestinal involvements in
inflammatory bowel disease: new insights into autoim-
mune pathogenesis.
Dig Dis Sci.
1999 Jan;44(1):1-13.
3.
Danese S, Semerano S, Papa A, et al. Extraintestinal
manifestations in inflammatory bowel disease.
World
J Gastroenterol.
2005 Dec 14;11(46):7227-7236.
4.
Loftus EV Jr., Harewood GC, Tremaine WJ, et al.
PSC-IBD: a unique form of inflammatory bowel
disease associated with primary sclerosing cholangitis.
Gut.
2005 Jan;54(1):91-96.
5.
DeVos M. Review article: Joint involvement in
inflammatory bowel disease.
Aliment Pharmacol Ther.
2004; 20(Suppl 4):36-42.
6.
Barrie A, Requiero M. Biologic therapy in the
management of extraintestinal manifestations of in-
flammatory bowel disease.
Inflamm Bowel Dis.
2007
Nov;13(11):1424-9.
7.
Tavarela, VF. Review article: Skin complications
associated with inflammatory bowel disease.
Aliment
Pharmacol Ther.
2004 Oct;20(Suppl 4):50-.3
8.
Timani S, Mutasim DF. Skin manifestations of
inflammatory bowel disease.
Clin Dermatol.
2008
May-Jun;26(3):265-73.
9.
Mintz R, Feller ER, Baar RL. Ocular manifestations
of inflammatory bowel disease.
Inflamm Bowel Dis.
2004 Mar;10(2):135-9.
10.
Venkatesh PG, Navanecthan U, Shen B. Hepatobi-
liary disorders and complications of inflammatory
bowel disease.
J Dig Dis.
2011 Aug;12(4):245-56.
11.
Shale M, Kanfer E, Panaccione R, Ghosh S. Hepa-
tosplenic T cell lymphoma in inflammatory bowel
disease.
Gut.
2008;57:1639-41.
12.
Tsiolakidou G, Koutroubakis IE. Thrombosis
and inflammatory bowel disease-the role of ge-
netic risk factors.
World J Gastroenterol.
2008
Jul;14(28):4440-4444.
13.
Basseri B, Enayati P, Marchevsky, A. Pulmonary
manifestations of inflammatory bowel disease: case
presentations and review.
J Crohns Colitis.
2010
Oct;4(4):390-7.
14.
Yilmaz A, Demirci NY, Hosgun D, et al. Pulmonary
involvement in inflammatory bowel disease. World J
Gastroenterol. 2010 Oct 21;16(39):4952-4957.
15.
Oikonomou K, Kapsoritakis A, Eleftheriadid S.
Renal manifestations and complications of inflam-
matory bowel disease.
Inflamm Bowel Dis.
2011
Apr;17(4):1034-45.
16.
Singh S, Kumar N, Corins EV, Kane SV. Neurologic
complication in patients with inflammatory bowel
disease: increasing relevance in the era of biologics.
Inflamm Bowel Dis.
2013 Mar-Apr;19(4):864-872.
17.
Bernstein CN, Leslie WD, Leboff MS. AGA techni-
cal review on osteoporosis in gastrointestinal diseases.
Gastro.
2003 Mar;124(3):795-841.
18.
Braun J, Brandt J, Listing J, et al. Two year main-
tenance of efficacy and safety of infliximab in the
treatment of ankylosing spondylitis.
Ann Rheum Dis.
2005 Feb;64(2):229-234.
19.
Murphy CC, Ayliffe WH, Booth A, et al. Tumor
necrosis factor alpha blockage with infliximab for
refractory uveitis and scleritis.
Ophthalmology.
2004
Feb;111(2):352-6.
20.
Ott C, Scholmerich A. Extraintestinal manifestations
and complications in IBD.
Nature Rev Gastroenterol
Hepatol.
2013 Oct;10(10): 585-595.